| Detected | Trial | Change |
|---|---|---|
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
Trial completed |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Primary completion moved earlier: 2026-07 -> 2026-05-23 |
| 2026-06-04 | NCT04164199 Study of Tislelizumab, Pamiparib, and Other Investigational Agents in Participants With… |
date change Completion moved earlier: 2026-07 -> 2026-05-23 |
| First Posted | Trial | Phase | Status |
|---|---|---|---|
| 2026-06-02 | NCT07621159 A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced… | Phase 1/2 | Not Yet Recruiting |
| 2026-05-18 | NCT07591597 A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of… | Phase 1/2 | Not Yet Recruiting |
| NCT ID | Title | Condition | Status |
|---|---|---|---|
| Phase 4 | |||
| NCT06562543 | A Trial to Evaluate the Safety and Activity of Fruquintinib in Minority Populations With… | Colorectal Cancer | Recruiting |
| NCT07446465 | FOLFOX Chemotherapy Combined With Fruquintinib and Serplulimab as First-Line Conversion… | Colorectal Cancer (Locally Advanced or Metastatic) | Not Yet Recruiting |
| Phase 3 | |||
| NCT07270991 | Trifluridine/Tipiracil + Fruquintinib Versus Trifluridine/Tipiracil Alone for Metastatic… | Metastatic Oesogastric Adenocarcinoma | Recruiting |
| NCT06497985 | A Study of Tucidinostat in Combination With Sintilimab and Bevacizumab in MSS/pMMR… | Colorectal Cancer | Recruiting |
| Phase 2 | |||
| NCT05954429 | A Study to Explore the Third-line Treatment of Fruquintinib Combined With Serplulimab in… | Colorectal Cancer | Recruiting |
| NCT07392346 | Safety and Efficacy of Fruquintinib Plus Nab-Paclitaxel and Iparomlimab and Tuvonralimab… | Gastric Cancer Adenocarcinoma Metastatic | Recruiting |
| NCT06992258 | A Randomized Phase 2 Trial of Fruquintinib and TAS-102 as Compared to Fruquintinib in… | Colorectal Cancer | Recruiting |
| NCT07011576 | A Study of Fruquintinib Plus FOLFIRI as Second-Line Treatment for Participants With… | Colon Cancer | Recruiting |
| NCT06356584 | Fruquintinib Combined With Sintilimab ± Radiotherapy for Third-line Treatment of… | Colorectal Cancer | Recruiting |
| NCT07136077 | A Phase 2 Trial of Fruquintinib and Tislelizumab in ctDNA-defined Minimal Residual… | Minimal Residual Disease | Recruiting |
| NCT07235293 | A Study to Test DSP107 in Combination With Atezolizumab in Comparison With Fruquintinib… | Colorectal Cancer | Recruiting |
| NCT07502014 | A Clinical Study of Iparomlimab and Tuvonralimab Combined With Fruquintinib and… | Metastatic Colorectal Cancer (CRC) | Not Yet Recruiting |
| NCT07510932 | Fruquintinib In Patients With Metastatic Colorectal Cancer Refractory to Standard… | Colon Cancer | Not Yet Recruiting |
| Phase 1/2 | |||
| NCT05867420 | A Study of ASKG915 in Patients With Selected Advanced Solid Tumors. | Advanced Solid Tumors | Recruiting |
| NCT07591597 | A Multicenter, Phase Ib/II Clinical Trial to Evaluate the Efficacy and Safety of… | Metastatic Colorectal Neoplasms | Not Yet Recruiting |
| NCT07621159 | A Phase Ib/II Study of HDM2017 in Combination With Standard of Care in Advanced… | Colorectal Cancer Metastatic | Not Yet Recruiting |
| Not specified | |||
| NCT06417892 | Fruquintinib and Albumin-paclitaxel Combined With or Without PD-1 Antibody in 2nd-line… | Gastric Cancer | Recruiting |
| NCT07124858 | Prospective National Cohort Evaluating Prognostic Factors for Efficacy of Fruquintinib… | Metastatic Colorectal Cancer (CRC) | Recruiting |